Disclosed are compounds which bind 4 integrins, where
the 4 integrin is preferably VLA-4. Certain of these compounds
also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated
by 4 integrins, where the 4 integrin is preferably
VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a
mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis,
AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue
transplantation, tumor metastasis and myocardial ischemia. The compounds can also
be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.